OncoCyte Stock
Focused on cancers with large patient populations and significant unmet need.
Sign up today and learn more about OncoCyte Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About OncoCyte Stock
OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.The company believes that better and earlier detection of cancer through liquid biopsies will: Improve patient outcomes Increase the life expectancy of cancer patients Significantly reduce health care costs Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.
Management
President & CEO
William Annett
CFO
RUSSELL SKIBSTED
Press
genomeweb - Jul, 25 2023
Oncocyte Initiates 1-for-20 Reverse Stock Splitmorningstar - Jul, 24 2023
Oncocyte Announces 1-For-20 Reverse Stock Splitthefly - Jun, 27 2023
OncoCyte begins manufacturing transplant blood testbiospace - May, 12 2023
Oncocyte Reports First Quarter 2023 Financial Resultsgenomeweb - Apr, 15 2023
Oncocyte Lays off 20 Percent of Workforcehubs - Apr, 14 2023
BioSpace Layoff Tracker 2023: Aeglea, Oncocyte, GentiBio and More Cut Staffbenzinga - Apr, 13 2023
Oncocyte's Announces Another Round Of Layoffs Leaving 20% Of Staff Impactedgenomeweb - Mar, 5 2023
People in the News at Personalis, Oncocyte, Guardant Health, Akoya Biosciences, Geneoscopy, Moregenomeweb - Dec, 19 2022
Oncocyte Laying off 40 Percent of Staff, Selling DetermaRx Testbiospace - Dec, 19 2022
Oncocyte Announces Initiatives to Focus Corporate Strategydlvr - Dec, 17 2022
Why The OncoCyte (OCX) Stock Dropped 21.95%marketwatch - Dec, 16 2022
Oncocyte cuts 40% of staffgenomeweb - Dec, 3 2022
People in the News at Oncocyte, PrognomiQ, BillionToOne, Haystack Oncology, Morebenzinga - Dec, 2 2022
Expert Ratings for OncoCyteglobenewswire - Nov, 30 2022
Oncocyte Announces Executive Leadership Changesbiospace - Nov, 12 2022
Oncocyte Reports Third Quarter 2022 Financial Resultsbenzinga - Aug, 18 2022
OncoCyte And 2 Other Stocks Under $1 Insiders Are Aggressively Buyinggenomeweb - Aug, 11 2022
Oncocyte Realigns Operations, Implements Cost Reduction Programsbiospace - Jul, 28 2022
Oncocyte to Announce Second Quarter 2022 Financial Resultsbenzinga - Jul, 14 2022
Oncocyte Enters $2B Market With Transplant Rejection Monitoring Testgenomeweb - May, 14 2022
Oncocyte Q1 Revenues Rise 27 Percent on DetermaRx Activityglobenewswire - Apr, 15 2022
Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrantsgenomeweb - Mar, 12 2022
Oncocyte Reports Sevenfold Increase in Q4 Revenues on Strong DetermaRx Growthprnewswire - Jan, 20 2022
Thinking about buying stock in Casper Sleep, Trip.com, Huazhu Group, OncoCyte, or 360 DigiTech?genomeweb - Dec, 26 2021
Oncocyte Switches Gears on Transplant Test Commercialization, Plans to Launch LDT Next Yeargenomeweb - Dec, 20 2021
In Brief This Week: Oncocyte, BioMérieux, Thermo Fisher Scientific, and Moregenomeweb - Aug, 11 2021
Oncocyte Sees $2M in Q2 Revenues, Beating Wall Street Estimatemassdevice - Apr, 20 2021
Oncocyte acquires Chronix Biomedicalthestreet - Dec, 15 2020
Oncocyte Soars on Licensing Deal With Chinese Firmgenomeweb - Nov, 13 2020
OncoCyte Posts $555K in Q3 Revenues, Net Loss Risesbuff - Jun, 16 2020
Oncocyte Transitions to Revenue Generation as Multiple Payers Begin DetermaRx™ Reimbursementsglobenewswire - Jan, 3 2020
OncoCyte Announces $7.6 Million Registered OfferingThe Herald - Jun, 27 2018
OncoCyte Corporation (AMEX:OCX) Has Yielded YoY Sales Growth ofYankee Analysts - Jun, 27 2018
Oncocyte Corp (OCX) Placed Under the LensPark City Caller - Jun, 26 2018
Is OncoCyte Corporation (AMEX:OCX) Headed For Earnings Growth?The Ledger Gazette - Jun, 24 2018
OncoCyte (OCX) Stock Price Up 37%The Lincolnian Online - Jun, 19 2018
OncoCyte Corp (NYSEAMERICAN:OCX) Sees Significant Decline in Short InterestGenomeWeb - May, 15 2018
OncoCyte Shrinks Q1 Net Loss; Expects Clinical Validation by Year's EndEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
